Should You Buy These 4 Quantum Computing Stocks Before 2027?

IonQ, Rigetti and D-Wave remain unprofitable, with Q2 adjusted EBITDA losses of $120.3 million, $5.1 million in revenue for Rigetti, and D-Wave revenue down slightly to $3.1 million; their cash balances are $3.0 billion, $541 million and $546 million, respectively. Their price-to-sales ratios range from 59 to 485, while meaningful commercialization remains years away and IonQ targets profitability by 2030. IBM offers a lower-risk, profitable alternative, reporting Q2 revenue up 1% to $17.2 billion and non-GAAP EPS up 5% to $2.93; it plans to spend $10 billion over five years and targets a large-scale fault-tolerant quantum computer by 2029.

Analysis

The key valuation fault line is not simply “profitable versus unprofitable”; it is whether technical progress converts into repeatable, economically meaningful workloads. For IONQ, RGTI and QBTS, acquisition-inflated growth or lumpy contract timing makes headline sales a weak signal. Track organic bookings, customer repeat rates, backlog conversion and cash burn per dollar of organic revenue. Cash delays financing pressure, but does not validate the business model; if milestones slip while burn persists, dilution and multiple compression can arrive well before runway becomes an issue.

Near term, these stocks remain vulnerable to sharp repricing around technical announcements because valuations embed distant commercialization. That same optionality makes outright shorts hazardous. Over 1–3 months, earnings quality and milestone credibility matter more than broad quantum-market forecasts. Over 6–18 months, evidence of recurring workloads—or a failure to demonstrate practical advantage—should increasingly separate platform providers from research-stage vendors. IBM has a different payoff: its core business cushions downside, but quantum investment only creates incremental value if deployments translate into measurable customer spend, not just engineering milestones. Large cloud and software platforms could also capture distribution economics even if they do not own the best hardware.

Contrarian point: cash-rich pure plays may survive long enough to benefit from breakthroughs, so high multiples alone are not a timing signal. Conversely, a technical “quantum advantage” milestone is not proof of customer ROI. The thesis weakens if pure plays show sustained organic bookings and improving burn, or if IBM’s promised timeline slips without commercially relevant workloads.

Key Decisions for Investors

• Prefer a staged relative-value position—long IBM against a smaller, diversified short basket of IONQ/RGTI/QBTS—only after confirming borrowing costs, liquidity and beta exposure. The aim is to own funded, diversified exposure while fading distant-duration valuations, not to bet on near-term insolvency. Reassess if pure-play organic bookings and cash efficiency improve materially or IBM’s quantum milestones slip.
• For IONQ, RGTI and QBTS, avoid treating reported sales growth as a buy signal until the next results clarify organic revenue, recurring customer demand and cash consumption. A deterioration in these measures supports underweighting; demonstrated repeat business is a thesis-falsifying upside catalyst.
• Avoid an unhedged outright short in the pure plays: ample reported cash and milestone-driven trading can create squeeze risk despite weak near-term economics. If downside exposure is needed, consider defined-risk options only after checking premiums and liquidity; no option trade is justified by the supplied data alone.
• Monitor IBM’s 2028–29 commercialization claims as a longer-dated catalyst. Evidence of customer workloads and incremental revenue would support the relative-value thesis; missed technical milestones or no economic adoption despite delivery would weaken it.